Loading…
Sonoma Pharmaceuticals, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -98.9% over 5Y.
today you would have $11.38▼ -98.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 16 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $1.27 | $3.64 | $2.69 | $3.60 | $22.40 | $91.20 | $145.20 | $87.20 | $127.80 | $981.00 | $907.20 | $1,035.00 | $1,287.00 | $3,132.00 | $3,843.00 | $6,615.00 | |
| P/E | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| HCWBHCW Biologics Inc. | $3.43 | — | 0.7x | — | -151.36% | $6.3M |
| ACXPAcurx Pharmaceuticals, Inc. | $1.44 | — | 0.8x | — | -128.11% | $6.19M |
| ENVBEnveric Biosciences, Inc. | $1.37 | — | 0.3x | — | -170.04% | $6.13M |
| VNRXVolitionrx Ltd | $0.45 |
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin fisures, sunburn, peeling, and eczema/atopic dermatitis; Gramaderm for the treatment of topical mild to moderate acne; Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription and over-the-counter product used to relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and Pediacyn, an atopic dermatitis hydrogel. The company also provides Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a range of pathogens; Ocucyn eyelid and eyelash cleanser; Ocudox for eye care; Sinudox for nasal irrigation; Microdacyn60 oral care solution to treat mouth and throat infections; and Podiacyn, a foot care product. In addition, it offers MicrocynAH, an HOCl-based solution used to relieve common symptoms of hot spots, scratches, skin rashes, post-surgical sites, and irritated animal skin; MicrocynVS, an animal care product; Nanocyn, a hospital-grade disinfectant; Acuicyn, a solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns, a disinfectant; and Endocyn, a root canal irrigation solution. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| — |
| 2.5x |
| — |
| — |
| 2.6x |
| — |
| — |
| — |
| P/S | 0.7x | 0.3x | 0.4x | 0.2x | 0.1x | 0.3x | 0.5x | 0.8x | 0.3x | 0.3x | 1.8x | 2.3x | 1.2x | 0.9x | 1.5x | 1.6x | 2.9x |
| P/B | 1.4x | 2.0x | 1.4x | 0.4x | 0.1x | 0.4x | 1.8x | 2.5x | 0.7x | 0.3x | 1.1x | 2.1x | 1.4x | 1.0x | 5.6x | — | 16.4x |
| EPS | -$1.89 | -$2.79 | -$10.63 | -$30.40 | -$38.40 | -$39.40 | -$44.80 | -$255.40 | -$569.80 | $396.00 | -$556.20 | -$765.00 | $486.00 | -$1,170.00 | -$1,683.00 | -$1,890.00 |
| Profit margin | -38.39% | -16.26% | -24.20% | -37.97% | -38.81% | -40.28% | -21.20% | -18.45% | -62.19% | -86.01% | 72.31% | -108.46% | -59.21% | 27.33% | -35.15% | -57.51% | -81.48% |
| ROE | -78.37% | -102.58% | -78.37% | -78.78% | -64.57% | -58.48% | -73.65% | -58.82% | -151.84% | -93.49% | 43.27% | -100.22% | -68.05% | 30.96% | -133.08% | — | -467.25% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $6.48M |
| XTLBXtl Biopharmaceuticals Ltd | $2.47 | — | — | — | -29.30% | $6.07M |
| BMRABiomerica Inc | $2.14 | — | 2.0x | — | -94.32% | $6.61M |